Japan has three main political parties-the ruling Liberal Democratic Party, the opposition Socialist Party and the Komeito Party, the political arm of the Soka Gakkai religious movement. I am a member ...

Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer based on a virus that selectively kills malignant cells.

It really comes from the way that I was trained as a dancer, that the music is always the impetus for movement. I listen to the music a lot. I fall asleep listening to the music. So it's just in ...

For the man who has everything, NIDEC Sankyo Corp. has refashioned the nostalgic music box into a 21st-century showpiece for well-heeled audiophiles. The electronic component manufacturing ...

Find Japan Musical near you including the best of musicals, plays, comedies, Broadway shows on tour, kid-friendly family shows & more. Powered By Sign-up Now for Japan Theatre News & Discounts Get ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards. Daiichi Sankyo, a pharmaceutical group boasting over ...

Daiichi Sankyo has signed an agreement with Japan’s Ministry of Health, Labour and Welfare (MHLW) to deliver 1.4 million doses of its omicron XBB.1.5-adapted monovalent mRNA [messenger ...

Daiichi Sankyo has a second approval in Japan for Ezharmia, its first-in-class dual EZH1 and EZH2 inhibitor, as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL).

Daiichi Sankyo will seek to maintain its edge over competitors in precision cancer therapies by pushing ahead with clinical trials of drug candidates being developed using new technology ...

Daiichi Sankyo announced that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Enhertu (trastuzumab deruxtecan) for the ...

Daiichi Sankyo Co. is in discussions to provide supplies of a potential coronavirus vaccine now being developed by AstraZeneca Plc and the University of Oxford for use in Japan. In a statement ...